Summary
4AB Chart
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?
ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
2 ETFs To Prepare You For A Potential Recession
I see a 50-60% chance of a recession in the next 12–24 months, so portfolio preparation is essential. I recommend the iShares Gold Trust Micro as a low-cost gold ETF that has outperformed during recent uncertainty and can hedge against downturns. I also like the iShares Core Dividend Growth ETF for its quality holdings, solid dividend growth, and resilience in volatile markets.
AbbVie Inc. Dividends
 4AB 2 months ago | Other | €1.39 Per Share |
| 4AB 5 months ago | Other | €1.39 Per Share |
| 4AB 8 months ago | Other | €1.32 Per Share |
| 4AB 11 months ago | Other | €1.32 Per Share |
| 4AB 12 Apr 2024 | Other | €1.32 Per Share |
AbbVie Inc. Earnings
| 31 Jul 2025 (In 3 weeks) Date | | 3.16 Cons. EPS | - EPS |
| 24 Jul 2025 (In 2 weeks) Date | | 3.18 Cons. EPS | - EPS |
| 23 Jul 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 24 Apr 2025 Date | | - Cons. EPS | - EPS |
| 31 Jan 2025 Date | | - Cons. EPS | - EPS |
| 4AB 2 months ago | Other | €1.39 Per Share |
| 4AB 5 months ago | Other | €1.39 Per Share |
| 4AB 8 months ago | Other | €1.32 Per Share |
| 4AB 11 months ago | Other | €1.32 Per Share |
| 4AB 12 Apr 2024 | Other | €1.32 Per Share |
| 31 Jul 2025 (In 3 weeks) Date | | 3.16 Cons. EPS | - EPS |
| 24 Jul 2025 (In 2 weeks) Date | | 3.18 Cons. EPS | - EPS |
| 23 Jul 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
| 24 Apr 2025 Date | | - Cons. EPS | - EPS |
| 31 Jan 2025 Date | | - Cons. EPS | - EPS |
AbbVie Inc. (4AB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has AbbVie Inc. ever had a stock split?
AbbVie Inc. Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Robert A. Michael CPA CEO | XBER Exchange | US00287Y1091 ISIN |
| US Country | 55,000 Employees | 15 Apr 2025 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
Overview
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.
Products and Services
- Humira: A therapeutic injection for various autoimmune diseases, including intestinal Behçet's disease and pyoderma gangrenosum.
- Skyrizi: Prescribed for patients with moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease, focusing on improving skin health.
- Rinvoq: Targets multiple conditions such as rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and several gastrointestinal diseases.
- Imbruvica: An oral medication for adults with various blood cancers, marking significant advancements in oncology.
- Epkinly and Elahere: Treatments tailored for different forms of lymphoma and cancer, showcasing AbbVie's innovations in targeted therapies.
- Venclexta/Venclyxto: Offers hope for patients battling blood cancers, through a regimen that interferes with cancer cell survival.
- Aesthetic Products: A range of facial injectables, plastics and regenerative medicine, body contouring, and skincare offerings that cater to aesthetic needs.
- Botox Therapeutic: Beyond cosmetic applications, this product is utilized for various therapeutic purposes, enhancing patient care.
- Vraylar: A medication designed to address depressive disorder, contributing to mental health treatment options.
- Duopa and Duodopa: These formulations provide relief for patients with advanced Parkinson's disease, improving quality of life.
- Ubrelvy and Qulipta: Target the acute treatment of migraine in adults, including both episodic and chronic forms.
- Ozurdex: An ocular implant designed to treat eye diseases, emphasizing AbbVie's contribution to ophthalmology.
- Lumigan/Ganfort and Alphagan/Combigan: Aimed at reducing intraocular pressure in conditions like open-angle glaucoma or ocular hypertension.
- Restasis: Helps increase tear production, addressing the needs of patients with dry eye disease.
- Mavyret/Maviret: Administered for the treatment of chronic hepatitis C virus (HCV) infection, representing a breakthrough in HCV treatment.
- Creon: A pancreatic enzyme therapy essential for patients with pancreatic insufficiency, aiding digestion.
- Lupron: Utilized for treating advanced prostate cancer, endometriosis, central precocious puberty, and uterine fibroids-related anemia.
- Linzess/Constella: Offers relief for irritable bowel syndrome with constipation and chronic idiopathic constipation.
- Synthroid: A synthetic thyroid hormone used to treat hypothyroidism, ensuring thyroid hormone levels are balanced.
Contact Information
